News

MBF Bioscience Announces the Acquisition of Vidrio Technologies

MBF Bioscience, a leading provider of bioscience image analysis tools, announced that it has completed the acquisition of Vidrio Technologies. Terms of the transaction were not disclosed.

Based in Ashburn, VA, Vidrio is a fast-growing provider of software and hardware components for laser scanning and two photon microscopes.

“Vidrio Technologies builds widely loved tools for researchers who utilize two photon and laser scanning microscopes to answer some of the toughest questions in biology,” says MBF Bioscience Founder and President Jack Glaser. “They have assembled a truly special team of engineers and I am thrilled that MBF will have the opportunity to be a part of the continued development, release, and support of Vidrio’s impressive products.”

“The team at Vidrio couldn’t be more excited to be joining forces with MBF,” says Vidrio Technologies CEO Bruce Kimmel. “We have grown rapidly in recent years and MBF’s large development team will be a great resource for us as we continue to invest in the development of industry-leading tools for bioscience researchers.”

Georg Jaindl, Senior Software Engineer at Vidrio Technologies said, “Vidrio has a pipeline full of exciting new products that we can’t wait to show our customers. By joining forces with MBF, we will be able to build these tools for our customers faster and provide even more responsive technical support than our customers already receive.”

Recent News

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the

07/07/2026

Governor Spanberger Announces Virginia Ranked #1 in Nation for Customized Workforce Training

Governor Abigail Spanberger announced today that Virginia is ranked number one in the United States for customized workforce training in the 22nd annual Business Facilities Rankings Report for the fourth consecutive year. Business Facilities, a leading national publication for economic development professionals, recognized the Virginia Talent Accelerator Program for its success in delivering workforce training